Linear Health Sciences LLC: Company Profile

Background

Overview

Linear Health Sciences LLC is a medical device company headquartered in Oklahoma City, Oklahoma, dedicated to enhancing patient safety and clinical efficiency through innovative medical tubing solutions. The company's flagship product, the Orchid Safety Release Valve (SRV), is a tension-activated device designed to prevent intravenous (IV) catheter dislodgement, thereby safeguarding patients and conserving hospital resources. IV dislodgement is a significant issue in U.S. healthcare systems, leading to over $2 billion in preventable waste annually.

Mission and Vision

Linear Health Sciences aims to improve the healthcare experience for patients, caregivers, and healthcare facilities by developing products that mitigate the risks associated with medical tubing dislodgement. The company's vision is to become a leading provider of safety solutions in the medical device industry, ensuring that every patient connected to a medical line is protected.

Key Strategic Focus

Core Objectives

Patient Safety: Develop and implement technologies that reduce the risk of IV catheter dislodgement, enhancing patient safety.

Clinical Efficiency: Create solutions that streamline hospital workflows and reduce the need for catheter replacements.

Cost Reduction: Address the financial burden of IV dislodgement, aiming to decrease the associated $2 billion annual cost in the U.S. healthcare system.

Areas of Specialization

Linear Health Sciences specializes in medical devices that focus on preventing unwanted disconnection of medical tubing, with a particular emphasis on IV catheter systems.

Key Technologies Utilized

Breakaway Safety-Valve Technology: The Orchid SRV employs proprietary breakaway safety-valve technology to prevent accidental IV catheter dislodgement.

Primary Markets Targeted

Hospitals and Healthcare Facilities: Institutions seeking to improve patient safety and reduce costs associated with IV catheter dislodgement.

Pediatric Care Units: Specialized focus on pediatric patients, who are particularly at risk for vascular access failures.

Financials and Funding

Funding History

Linear Health Sciences has secured funding through various channels, including grants and partnerships. In August 2022, the company received a seed grant from the West Coast Consortium for Technology & Innovation in Pediatrics (CTIP) to accelerate projects aimed at improving the safety and delivery of care to infants and children.

Total Funds Raised

Specific details regarding the total funds raised by Linear Health Sciences are not publicly disclosed.

Notable Investors

The company has partnered with organizations such as CTIP and Alliance Medical to advance its product development and distribution efforts.

Intended Utilization of Capital

The capital raised is primarily allocated towards product development, clinical trials, regulatory approvals, and expanding market reach for the Orchid SRV and other safety technology solutions.

Pipeline Development

Key Pipeline Candidates

Orchid SRV Type D Device: An extension of the Orchid SRV designed for use in surgical/wound, nephrostomy, and abscess drainage applications.

Stages of Development

Clinical Trials: The Orchid SRV has undergone clinical evaluations, demonstrating high acceptance rates among healthcare providers.

Regulatory Approvals: The company has received FDA clearance for the Orchid SRV, with an expanded indication for its use.

Target Conditions

IV Catheter Dislodgement: Preventing accidental dislodgement in adult and pediatric patients.

Surgical/Wound Care: Enhancing safety in surgical and wound care settings.

Anticipated Milestones

Product Launches: Introduction of the Orchid SRV Type D device into the market.

Clinical Acceptance: Achieving widespread adoption in healthcare facilities.

Technological Platform and Innovation

Proprietary Technologies

Breakaway Safety-Valve Technology: A patented mechanism that activates under tension to prevent IV catheter dislodgement.

Significant Scientific Methods

Clinical Simulation Testing: Evaluations demonstrating a 91.1% prevention rate of IV dislodgement across all test groups.

Leadership Team

Deon Miller – President & Chief Executive Officer

Deon Miller brings over 30 years of experience in executive, commercial, and operations leadership within the global medical device and biotech industries. His expertise includes team management, P&L management, customer service, and new business development.

Renae Franz – Chief Operating Officer & Chief Commercial Officer

Renae Franz has over 30 years of experience in sales, marketing, and product development within the medical device industry. She has commercialized over 200 medical technologies and is a named inventor on three USPTO-issued patents.

Dan Clark – Co-Founder, Chief Technology Officer

Dan Clark has nearly 20 years of experience in medical device innovation and development, focusing on product innovation and scalability. He has played a pivotal role in guiding both product and company lifecycles at Linear Health Sciences.

Casey Harness – Chief Administration Officer & Director of Operations

Casey Harness brings over a decade of experience working with and funding emerging technologies and start-up companies. He holds a Bachelor of Science in Biomedical Engineering from Yale University and focuses on strategic alignment and operational efficiency at Linear Health Sciences.

Market and Competitor Analysis

Market Insights and Dynamics

The medical device industry, particularly in vascular access and infusion therapy, is experiencing growth due to increasing patient safety concerns and demand for cost-effective solutions. The market for devices like the Orchid SRV is estimated to be over $1 billion annually.

Competitor Overview

Medtronic LATAM: A leading global medical device company with a diverse product portfolio.

PRIONTEX: Specializes in infection prevention and control products.

ZimVie Dental: Focuses on dental implant solutions.

Strategic Collaborations and Partnerships

Alliance Medical: Entered into an exclusive distribution agreement for the Orchid SRV, providing access to over 10,000 customers across the U.S.

Premier, Inc.: Awarded a national group purchasing agreement for the IV Therapy - Needleless Connectors category, facilitating broader adoption of the Orchid SRV.

Operational Insights

Linear Health Sciences differentiates itself through its proprietary breakaway safety-valve technology, addressing a significant unmet need in preventing IV catheter dislodgement. Strategic partnerships with distribution and purchasing organizations enhance its market reach and adoption.

Strategic Opportunities and Future Directions

The company plans to expand its product line to address other medical tubing applications, leveraging its core technology. Ongoing clinical evaluations and partnerships aim to increase adoption rates and demonstrate cost savings to healthcare providers.